Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Summary

The purpose of this study is to assess the safety and efficacy of bimatoprost in patients with glaucoma or ocular hypertension

Timeline

Start

2005-12

Primary completion

2007-06

Completion

2007-06

Outcome

Mixed primary results

paper The primary efficacy measure was IOP. PMID 20346780 ↗

paper Bimatoprost 0.01%, but not bimatoprost 0.0125%, was equivalent in efficacy to bimatoprost 0.03% PMID 20346780 ↗

Publications

• Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010 Apr;149(4):661-671.e1. doi: 10.1016/j.ajo.2009.12.003.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimatoprost	Other / unclassified	0.01 %	—
Subject	Bimatoprost	Other / unclassified	0.0125 %	—
Subject	Bimatoprost	Other / unclassified	0.03 %	—

Indications